Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.37 |
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.33 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396429 | 0.93 | NTRK1 (0.40) | TLK2NTRK1JAK3GSK3BKIT | |
| SCHEMBL395038 | 0.93 | MAPK14 (0.38) | MAPK14TLK2NTRK1JAK3GSK3B | |
| SCHEMBL399277 | 0.89 | TLK2 (0.47) | MAPK14TLK2NTRK1JAK3GSK3B | |
| SCHEMBL393970 | 0.89 | NTRK1 (0.44) | MAPK14TLK2NTRK1GSK3BKIT | |
| SCHEMBL396159 | 0.86 | FLT3 (0.47) | TLK2NTRK1KITFLT4KDR | |
| SCHEMBL396154 | 0.85 | MAPK14 (0.39) | MAPK14TLK2NTRK1JAK3GSK3B | |
| SCHEMBL399058 | 0.85 | FLT3 (0.48) | TLK2NTRK1JAK3GSK3BKIT | |
| SCHEMBL398243 | 0.84 | TLK2 (0.48) | TLK2NTRK1JAK3GSK3BKIT | |
| SCHEMBL396850 | 0.84 | NTRK1 (0.53) | TLK2NTRK1KITFLT4KDR | |
| SCHEMBL394525 | 0.83 | FLT3 (0.51) | TLK2NTRK1KITFLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | claimed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |